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Abstract: To date, in pediatric field, various hematological malignancies are increasingly treated 
with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Iron overload and systemic 
siderosis often occur in this particular cohort of patients and are associated with poor prognosis. 
We describe herein the case of two allo-HSCT patients, on treatment with deferasirox; they 
showed histopathological elements compatible with venoocclusive disease or vanishing bile 
duct syndrome in ductopenic evolution before deferasirox started. The first patient developed 
drug-induced liver damage with metabolic acidosis and the second one a liver impairment with 
Fanconi syndrome. After withdrawing deferasirox treatment, both patients showed improvement. 
Measurements of drug plasma concentrations were performed by HPLC assay. The reduction 
and consequent disappearance of symptoms after the suspension of deferasirox substantiate its 
role in inducing hepatic damage, probably enabling the diagnosis of drug-induced liver dam-
age. But the difficulties in diagnosing drug-related toxicity must be underlined, especially in 
compromised subjects. For these reasons, in patients requiring iron-chelating therapy, close and 
careful drug therapeutic monitoring is strongly recommended.
Keywords: deferasirox, allogeneic hematopoietic stem cell transplantation, allo-HSCT, 
pediatric, ductopenia, therapeutic drug monitoring, adverse events
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an increasingly 
used treatment modality for a wide variety of hematological malignancies and benign 
disease in the pediatric population. Iron overload (IO) has been associated with poor 
prognosis in patients undergoing allo-HSCT.1–5 Systemic siderosis in this cohort of 
patients is multifactorial and is not exclusively due to intense transfusion regimen.6 
Intensive cytotoxic therapy before HSCT destroys both bone marrow and neoplastic 
cells, releasing internal iron contents from cells and increasing free iron concentrations.7 
High-intensity myeloablative conditioning prior to HSCT can damage hepatic cells, 
which releases cellular iron pools and increases further iron load.8
Liver dysfunction (LD) is a common problem in these patients, both before and after 
transplantation. Almost half of pediatric HSCT patients have laboratory evidence of 
LD before transplantation, and 74% to 85.5% have post-transplantation transaminase 
elevations.9,10 Many causes of LD are well known, such as graft-versus-host disease 
(GVHD), drug hepatotoxicity, viral hepatitis, sepsis, venoocclusive disease (VOD), 
and disease recurrence. Nevertheless, a lesser proportion of liver complications are 
still classified as of undetermined cause.
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Deferasirox (DFX), an oral iron chelator, is widely used 
for the treatment of patients with IO. Excessive iron accumu-
lation often results in tissue damage and organ failure; it has 
been shown that pre-HSCT chelation with DFX leads to a 
rapid decrease in the labile plasma iron, improving survival. 
However, there are only few studies regarding the effects of 
chelation therapy in the post-transplant period in a pediatric 
setting or about the safety and tolerability of DFX in pediatric 
patients who developed LD after allo-HSCT.2,11
The aim of our study was to describe the adverse events 
(AEs) observed in two allo-HSCT patients treated with DFX. 
We have analyzed the development of symptoms before and 
after therapy discontinuation and the possible association 
with DFX.
Case reports
Case 1
The first patient was a 4-year-old male child (whose mother 
was an Ethiopian) affected by acute lymphoblastic leukemia 
who underwent allo-HSCT after total body irradiation (TBI)-
based myeloablative conditioning. GVHD prophylaxis 
was performed with tacrolimus only. Prophylaxis of liver 
complications was performed with ursodeoxycholic acid 
(UDCA), 30 mg/kg/day, from the first day of conditioning. 
During the pre-transplant work-up, the child was subjected 
to abdominal magnetic resonance evaluation of abdominal 
organ iron concentration. He was found to have severe IO 
with an iron concentration value higher than 200 µmol/g 
(normal value: ,40 µmol/g) in three of the four organs 
evaluated (ie, in spleen, bone, and liver, except pancreas), 
and the child underwent chelation therapy with deferoxamine 
(30 mg/kg/day, continuous intravenous infusion) during the 
entire stay in the Transplant Unit.
The post-transplantation period was complicated by a 
severe VOD, with a complete inversion of the portal flow 
and an important ascite (Figure 1). The severity of the clinical 
picture was further complicated by a hyperacute GVHD, 
characterized by hypertransaminasemia with aspartate 
aminotransferase and an alanine aminotransferase value 
higher than 800 U/L (normal values: ,38 U/L and ,25 U/L, 
respectively). The portal flow returned to normal after 10 days 
of defibrotide treatment. Hepatic GVHD resolved completely 
after three doses of infliximab.
After ascites resolution, a liver biopsy was performed 
and a histological evaluation showed the presence of 
central ischemic-hemorrhagic necrosis suggestive of VOD 
and a high degree of IO. Another histological feature was 
ductopenia (absence of interlobular bile ducts in portal tracts) 
suggestive of liver GVHD (Figure 2).
The patient underwent a second MRI-based iron load 
evaluation before discharge from our Transplant Unit and 
showed a general worsening of iron accumulation. All four 
abdominal organs evaluated had an abnormal iron concen-
tration. The liver, spleen, and bone showed a higher degree 
of siderosis compared to pre-transplant values. Ferritin 
values stabilized around 3,000 ng/mL (normal range: 
20–300 ng/mL).
Therefore, the patient was treated with DFX at a dosage 
of 375 mg/day (17.6 mg/kg). One month later, he was read-
mitted to our Unit with a marked deterioration of clinical 
conditions. He experienced fatigue, weakness, nausea, 
vomiting, abdominal pain, and anorexia that had begun one 
?????
????????
Figure 1 Case 1: color Doppler sonographic evaluation. Complete inversion of the 
portal venous flow.
Figure 2 Case 1: center lobular hemorrhagic confluent liver cells necrosis around a 
central vein showing few inflammatory infiltrates within lumen, suggesting diagnosis 
of venoocclusive disease (H&e, 100×).
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week before. Laboratory investigations on admission showed 
a normal white blood cell count with mild neutropenia, 
a normal platelets count, and hemoglobin concentration. 
His liver and renal function was mildly deranged. Further-
more, he was found to have a metabolic acidosis.
Primary disease recurrence was excluded. Prednisone at 
a dosage of 1 mg/kg was added to tacrolimus as systemic 
GVHD was suspected. To correct acidosis, the patient was 
hydrated by administering electrolyte solution enriched with 
bicarbonate.
Measurement, by high performance liquid chromatogra-
phy (HPLC) assay, previously described and validated,12,13 
of DFX plasma concentration confirmed a moderate 
increase of the drug plasmatic level (C
trough
 =27 µM; normal 
C
trough
 value ,20 µM; C
DFX
/D
DFX
 ratio =0.56). Tacrolimus 
therapeutic plasma concentrations were maintained at 
about 10 ng/mL.
He continued to demonstrate mild liver and renal dysfunc-
tion during the following month, while metabolic acidosis 
progressively worsened. The child underwent another liver 
biopsy that showed a histological feature suggestive of 
drug-induced liver injury (DILI) (Figure 3). After 79 days 
of chelation treatment, DFX was immediately stopped. 
His biochemical parameters normalized rapidly after dis-
continuation of DFX and the bicarbonate supplement was 
stopped two weeks later (see Table 1).
Case 2
The second clinical case was a 16-year-old male affected 
by X-linked lymphoproliferative syndrome. The diagnosis 
was performed at the beginning of January 2012, after a 
severe Epstein–Barr virus infection complicated by hepatic 
and respiratory failure, and erythrophagocytic histiocytosis 
affecting the brain.
In April 2012, he underwent a segmentectomy of the 
upper lung lobe, with a histological diagnosis of lymphoma-
toid granulomatosis. Then, he was treated with rituximab, 
vincristine, and dexamethasone.
In April 2013, after a busulfan-based myeloablative con-
ditioning, he underwent a matched unrelated donor-HSCT. 
GVHD prophylaxis was performed with tacrolimus and 
mycophenolate mofetil (MMF). The post-transplant period 
was uneventful and MMF was stopped at day +30.
In April 2014, one year later, the patient underwent a 
liver biopsy for a mild but steady alteration of liver func-
tional tests (LFT). The histological report highlighted portal 
tracts characterized by minimal fibrosis and marginal biliary 
ductular proliferation; numeric reduction of the interlobular 
bile ducts present in one of the eight portal tracts of the 
sample; Kupffer cells hyperplasia; and reticuloendothelial 
siderosis (2–3 degree). Widespread structural anomalies 
of the portal venous vessels appear numerically increased, 
with dilated lumen, sometimes herniated in the perivascular 
parenchyma (Figure 4).
The histological picture was compatible with chronic 
GVHD associated with vascular lesions such as hepatoportal 
sclerosis.
The MMF was again added to tacrolimus therapy and 
was suspended in May 2015, one year later. In June 2015, 
after a complete normalization of the LFT, tacrolimus was 
also stopped. The patient underwent an MRI-based iron-
load evaluation that demonstrated moderate liver siderosis 
(LIC 140 µmol/g). Ferritin also stabilized at values above 
2,000 ng/mL. At the end of June 2015, chelation therapy 
was started with DFX (1,500 mg/day; 26.4 mg/kg). The only 
concomitant drug was UDCA.
In July 2015, the patient returned to the observation of 
clinicians due to aggravating asthenia, which had started 
about 20 days earlier and became more complicated in the 
previous days, with symptoms such as severe abdominal 
pain, persistent vomiting, and anorexia, in particular after 
the intake of DFX.
A physical examination showed poor general condi-
tions, weight loss of 8 kg in the past 2 weeks, pallor, signs 
of dehydration, polypnea without dyspnea, tachycardia, and 
palpable liver at 2 cm from the costal arch. No other abnor-
malities were found.
Figure 3 Case 1: liver with normal architecture; inflammatory infiltrate is 
completely absent. Diffuse swelling of liver cells cytoplasm suggesting toxic-related 
damage (H&e, 40×).
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Laboratory tests showed a severe impairment of liver and 
renal functions; the patient was found to have metabolic aci-
dosis (see Table 2). Urinalysis showed abnormal proteinuria 
(192.9 mg/24 hours), albuminuria (25.89 mg/24 hours), 
β2-microglobulinuria (.50,000 ng/mL), and glycosuria 
(113 mg/24 hours), suggesting proximal tubular dysfunction. 
The patient was hydrated and corrected for acidosis with 
bicarbonates. As DFX liver toxicity associated with Fanconi 
syndrome was suspected, therapeutic drug monitoring of 
DFX was performed. It showed a minimum plasma concen-
tration (C
trough
) of 207 µM (C
DFX
/D
DFX
 ratio =2.93).
DFX was immediately discontinued. Four days later, 
fatigue and gastrointestinal symptoms cleared and the patient 
gained 3 kg of weight. One month later, LFT and laboratory 
findings associated with Fanconi syndrome were normal. 
DFX was not rechallenged to the patient and no recurrence 
of LD or Fanconi syndrome was evident for more than 
2 years.
Results
DFX is an oral iron-chelating agent used to treat chronic IO. 
It binds two iron molecules with high affinity and specificity, 
thus forming a stable complex with each iron (Fe3+) atom.14 
Table 1 Case 1: laboratory test results
Laboratory tests Conventional 
units
Reference 
range values
January 
2017*
February 
2017
March 
2017
April 
2017
Neutrophils ×103/µL 1.8–8.5 1.22 1.50 4.31 2.65
Lymphocytes ×103/µL 1.5–7.0 0.53 0.9 0.6 0.7
Platelets ×103/µL 150–450 # # # #
Hematocrit % 37.0–45.0 # 36.4 # #
Hemoglobin g/dL 10.5–13.5 # # 14.0 #
pH Na 7.350–7.450 7.309 7.31 7.314 #
pCO2 mmHg 38–52 # # 35 #
pO2 mmHg 83–108 # 45 # #
CO2 meq/L 19–29 20 17 16 22
HCO3
− meq/L 21–28 19 18 17 #
Be mmol/L −1.5 to +3.0 −3.6 −6.1 −7.6 −0.3
Natrium meq/L 135–145 # # 134 #
Phosphorus mg/dL 4.33–7.21 # 2.12 2.34 3.83
Magnesium mg/dL 1.80–2.30 # 1.74 1.21 1.22
Blood creatinine mg/dL 0.26–0.55 0.73 0.66 0.65 #
Blood urea nitrogen mg/dL 16–45 56 54 57 #
Blood bilirubin mg/dL 0.18–0.88 # # 0.95 #
Blood direct bilirubin mg/dL 0.04–0.20 0.29 0.27 0.26 #
asT U/L 10–34 45 41 52 #
aLT U/L 10–45 68 102 98 44
alkaline phosphatase U/L 142–335 # 354 460 #
g-GT U/L 5–14 # # 14 14
Bile salts µmol/L ,6 38.4 61.8 59.8 12.4
β2-microglobulin ng/mL 1,010–1,730 2,546 3,417 3,994 1,980
β2-microglobulinuria ng/mL ,300 # 23,052 12,500 #
Ferritin ng/mL 20–300 2,519 1,088 563.3 336.4
Liver biopsy Na Na Na Na X Na
DFX Na Na TDM§ Na stopped** Na
Tacrolimus (TDM) ng/mL Na 11.8 11.6 9.3 9.9
Notes: *Lab tests performed one month after starting DFX treatment. **DFX was stopped after 79 days of treatment. §TDM performed at Ctrough plasma concentration. 
Checklist reports only lab results that are out of normal range. # Normal value.
Abbreviations: Be, base excess; asT, aspartate aminotransferase; aLT, alanine aminotransferase; g-GT, gamma-glutamyl transferase; DFX, deferasirox; TDM, therapeutic 
drug monitoring; Na, not applicable.
Figure 4 Case 2: widespread structural anomalies of the portal venous vessels 
with dilated lumen, sometimes herniated in the perivascular parenchyma (CD34 
immunoreaction, 40×).
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DFX is licensed for use as first-line therapy for chronic blood 
transfusion-related IO in patients aged 2 years and older.15
Although its use represents a great improvement in terms 
of patients’ quality of life, there have been reports of several 
AEs in both adult and pediatric patients.
Mild AEs are the most frequently reported in pediatric 
and adult patients with transfusion-dependent anemias, 
for example, transient gastrointestinal issues in 15%, skin 
rashes in 11%, and mild, dose-dependent increases in serum 
creatinine in 38% of patients.15 Uncommon, but potentially 
severe, AEs are renal failure, gastrointestinal bleeding, hyper-
sensitivity reactions, and bone marrow suppression mostly 
in patients with pre-existing hematologic disorders.16
Few data are available on tolerability and safety of DFX 
in allo-HSCT recipients. Jaekel et al have documented drug-
related AEs in 71.1% patients.3
As of December 2017, EudraVigilance (the European 
database of suspected adverse drug reaction reports) had 
identified 1,679 individual cases of suspected adverse drug 
reactions for DFX in the European Economic Area and 
11,570 in the non-European Economic Area.17 Independent 
of age and Economic Area, the number of individual cases 
of reported suspected hepatobiliary reactions for DFX was 
920 (29 cases of DILI, 2 cases of VOD, and 9 cases of bile 
duct obstruction or stenosis) and renal and urinary disorders 
was 1,774. EudraVigilance reports 101 individual cases of 
suspected metabolic acidosis, 62 cases of acquired Fanconi 
syndrome, 17 cases of acidosis, and 4 cases of hyperchlo-
remic acidosis. Several single cases of clinically apparent 
liver injury, which was often severe and occasionally fatal, 
arising during DFX therapy have been reported. The onset 
of acute liver injury occurred in a period ranging from a few 
days to eight weeks after beginning DFX, and the injury was 
usually hepatocellular. Immunoallergic and autoimmune 
features were absent. Once DFX was stopped, recovery was 
usually rapid but some cases were affected by progressive 
liver injury and hepatic failure. DFX is sold with a health 
warning regarding hepatotoxicity and a recommendation 
for regular monitoring of serum bilirubin and aminotrans-
ferase levels.18
We have described herein cases of two allo-HSCT 
patients who were treated with DFX; they showed histopatho-
logical elements compatible with VOD or vanishing bile duct 
syndrome in ductopenic evolution before DFX started. The 
first patient developed DILI with metabolic acidosis and the 
second one a liver impairment with Fanconi syndrome. After 
withdrawing DFX treatment, both patients improved.
According to both direct and indirect evidence, the 
main pathway of the DFX metabolism is through hepatic 
glucuronidation to metabolites M3 (acyl glucuronide) 
and M6 (2-O-glucuronide) and it is eliminated by biliary 
excretion mainly through the feces (78.5%–86.9% over 
7 days).19,20
We hypothesized that the DFX elimination pathway 
may not work optimally in these two patients; the biliary 
tract injury, leading to the reduction of the metabolism 
and biliary elimination of the drugs, could be considered 
the main cause of DFX overload in our patients, also 
confirmed by high DFX plasmatic concentrations (26 µM 
and 207 µM, respectively). Therefore, the excess of free 
DFX molecules cannot be effectively eliminated and it 
accumulates in blood and in organs, such as the liver and 
kidney, leading to a worsening of the liver damage (DILI) 
and metabolic acidosis as observed in our first patient (Pt 1) 
and the development of Fanconi syndrome in the second 
patient (Pt 2).
The mechanism of occurrence of liver injury during DFX 
therapy is still unclear. Hepatocellular injury may be caused 
due to the intrinsic toxicity of DFX which determined direct 
damage to the hepatocytes, associated with elevated serum 
transaminase levels, and a worsening outcome in patients 
with pre-existing liver disease as a result of IO.18 Patients 
affected by hepatic dysfunction often have acid-base dis-
orders and tend to be more susceptible to the development 
of metabolic acidosis.21 Moreover, in agreement with ScP 
and the EudraVigilance database, “… there have been post-
marketing reports of metabolic acidosis occurring during 
treatment with deferasirox. Acid-base balance should be 
monitored as clinically indicated in these populations”.
Table 2 Case 2: laboratory test results
Laboratory tests Conventional 
units
Reference 
range values
July 
2015
WBC ×103/µL 4.50–13.50 4.6
Neutrophils ×103/µL 1.8–8.5 1.2
Platelets ×103/µL 150–450 91
Hemoglobin g/dL 10.5–13.5 9.6
pH 7.350–7.450 7.2
HCO3
− meq/L 21–28 15
Be mmol/L −1.5 to +3.0 −9.6
Potassium meq/L 3.50–5.10 2.1
Phosphorus mmol/L 1.3–2.3 1.3
Blood creatinine mg/dL 0.26–0.55 2.21
Blood urea nitrogen mg/dL 16–45 98.8
Blood bilirubin mg/dL 0.18–0.88 2.70
Blood direct bilirubin mg/dL 0.04–0.20 1.62
asT U/L 10–34 213
aLT U/L 10–45 215
LDH U/L 136–260 454
Bile salts µmol/L ,6 68.4
β2-microglobulin ng/mL 1,010–1,730 2,889
Abbreviations: WBC, white blood cells; Be, base excess; asT, aspartate 
aminotransferase; aLT, alanine aminotransferase; LDH, lactate dehydrogenase.
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The data in the literature also show DFX renal toxicity 
in adult and pediatric patients, with an increase in plasma 
creatinine and onset of proteinuria in about 35% of adult 
patients and in 19%–50% of pediatric patients.22 As widely 
reported, several drugs show a direct toxicity to the renal 
proximal tubule and can cause Fanconi syndrome; among 
them, DFX has also been recently reported to be associated 
with Fanconi syndrome.23,24 By increasing hemodynamic iron 
removal, DFX causes elevated iron absorption in organs, 
mitochondrial dysfunction, and vacuolization of proximal 
tubular epithelial cells together with a diminished excretion 
of hydrogen ions (H +), which is consistent with Fanconi 
syndrome. All of these could lead to the development of 
acidosis.25
Our patients did not experience plasma electrolyte dis-
turbance prior to treatment with DFX during the routine 
follow-up. In our two patients, the first signs of acidosis 
appeared only after starting DFX – in the first patient, labora-
tory findings were compatible with mild renal dysfunction 
and in the second patient, laboratory findings were compatible 
with Fanconi syndrome. Hence, DFX was discontinued in 
both patients, and acidosis was corrected.
It is reasonable to think that the development of acidosis 
in both cases is correlated with the overload of DFX and its 
potential toxicity, but we believe that, in the first patient, 
there was also a clear hepatic histopathological feature, 
as revealed by the biopsy, that contributed to the onset of 
the acidosis itself that developed more slowly over time 
(29 days of therapy). According to our hypothesis, the second 
patient by contrast rapidly developed acidosis (Fanconi 
syndrome) following a greater direct renal toxic effect of the 
drug associated with hepatic damage, considering also the 
brevity of treatment before the onset of the clinical condi-
tion (12 days of therapy) and the high plasma concentration 
detected (279 µM).
In our patients, other potential causes of metabolic 
acidosis were ruled out, although the nephrotoxic effects 
of tacrolimus are also a major concern; coadministration 
of DFX with tacrolimus could have increased the risk of 
metabolic acidosis.26
The Naranjo adverse drug reaction scale27 was used to 
assess the probability that DFX caused acidosis. Based on 
this scale, there is a “probable” (Naranjo score =5) associa-
tion between DFX and the development of acidosis in both 
patients.
In line with the literature, our clinical cases do not seem 
to be the first to highlight the onset of metabolic acidosis 
due to the use of DFX also in a pediatric setting.23,26,28,29 
The reduction and consequent disappearance of symptoms 
after the suspension of DFX substantiate its role in inducing 
hepatic damage, probably enabling the diagnosis of DILI. 
The clinical suspicion of drug toxicity was also supported by 
the measurement of DFX plasma concentrations.
Conclusion
One of the greatest difficulties when dealing with iron chela-
tion therapy is tailoring the dose of chelators to the individual 
patient. This has to be done according to the patient’s clinical 
condition and considering available pharmacokinetic data. 
Indeed, it is known that DFX pK parameters show a wide 
intra- and interindividual variability that strongly supports 
the adoption of therapeutic drug monitoring protocols. 
To date, DFX pharmacokinetic data in pediatric allo-HSCT 
patients is still lacking. In this particular cohort of patients, 
various factors can affect DFX kinetics, thereby exposing 
the patient to a non-negligible risk of adverse reactions. 
Increasingly, clinical practice requires a complex assess-
ment of the interaction between the metabolic effects of the 
drug and individual susceptibility through pharmacokinetic 
approaches.
Based on our previously study in pediatric HSCT patients, 
we suggest a DFX starting dose of 10 mg/kg/day with close 
monitoring of DFX plasma concentrations (normal C
trough
 
value ,20 µM), in order to reduce the incidence of AEs and 
the discontinuation of therapy. Moreover, monitoring DFX 
plasma concentrations over time may be useful in restoring 
adequate exposure to the drug following any changes in the 
clinical picture of patients which can lead to a variation in 
drug dosage.
The difficulties in diagnosing drug-related toxicity must 
be underlined, especially in compromised subjects. For 
these reasons, in patients requiring iron-chelating therapy, 
close and careful drug therapeutic monitoring is strongly 
recommended.
Acknowledgments
The authors would like to thank the participating patients. 
Written informed consent has been provided by the patients 
to have the case details and any accompanying images 
published. The authors would like to thank Dr Claire Marie 
O’Neil for her English language support. The authors have 
not presented or posted this study or data anywhere and 
have solely submitted it to this journal. The study did not 
receive any source of funding from a sponsor.
 
Th
er
ap
eu
tic
s 
an
d 
Cl
in
ica
l R
isk
 M
an
ag
em
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
25
1.
17
2.
10
 o
n 
11
-S
ep
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Therapeutics and Clinical Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal
Therapeutics and Clinical Risk Management is an international, peer-
reviewed journal of clinical therapeutics and risk management, focusing 
on concise rapid reporting of clinical studies in all therapeutic areas, 
outcomes, safety, and programs for the effective, safe, and sustained 
use of medicines. This journal is indexed on PubMed Central, CAS, 
EMBase, Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Therapeutics and Clinical Risk Management 2018:14 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1655
Deferasirox chelation therapy in pediatric HsCT recipients
Author contributions
All authors contributed toward data analysis, drafting and 
critically revising the paper, gave final approval of the ver-
sion to be published, and agree to be accountable for all 
aspects of the work.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Reddy K, Eng J, Carlson C, Ginsberg J, Fish J. Impact of transfu-
sional support for childhood cancer – peering behind the iron curtain: 
(Poster 119). Pediatr Blood Cancer. 2011;56:908.
 2. Inati A, Kahale M, Sbeiti N, et al. One-year results from a prospec-
tive randomized trial comparing phlebotomy with deferasirox for the 
treatment of iron overload in pediatric patients with thalassemia major 
following curative stem cell transplantation. Pediatr Blood Cancer. 
2017;64(1):188–196.
 3. Jaekel N, Lieder K, Albrecht S, et al. Efficacy and safety of deferasirox 
in non-thalassemic patients with elevated ferritin levels after allogeneic 
hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016; 
51(1):89–95.
 4. Sivgin S, Baldane S, Akyol G, et al. The oral iron chelator deferasirox 
might improve survival in allogeneic hematopoietic cell transplant 
(alloHSCT) recipients with transfusional iron overload. Transfus 
Apher Sci. 2013;49(2):295–301.
 5. Sivgin S, Eser B, Bahcebasi S, et al. Efficacy and safety of oral 
deferasirox treatment in the posttransplant period for patients who 
have undergone allogeneic hematopoietic stem cell transplantation 
(alloHSCT). Ann Hematol. 2012;91(5):743–749.
 6. Maximova N, Gregori M, Boz G, et al. MRI-based evaluation of mul-
tiorgan iron overload is a predictor of adverse outcomes in pediatric 
patients undergoing allogeneic hematopoietic stem cell transplantation. 
Oncotarget. 2017;8(45):79650–79661.
 7. Evens AM, Mehta J, Gordon LI. Rust and corrosion in hematopoietic 
stem cell transplantation: the problem of iron and oxidative stress. 
Bone Marrow Transplant. 2004;34(7):561–571.
 8. Gordon LI, Brown SG, Tallman MS, et al. Sequential changes in 
serum iron and ferritin in patients undergoing high-dose chemotherapy 
and radiation with autologous bone marrow transplantation: possible 
implications for treatment related toxicity. Free Radic Biol Med. 1995; 
18(3):383–389.
 9. Subbarao G, Haut PR, Johnson CS, Gowan D, Molleston JP. Incidence, 
etiology, and risk factors for liver dysfunction in children following 
hematopoietic stem cell transplantation. Pediatr Transplant. 2006;10: 
682–689.
 10. Locasciulli A, Testa M, Valsecchi MG, et al. Morbidity and mortality 
due to liver disease in children undergoing allogeneic bone marrow 
transplantation: a 10-year prospective study. Blood. 1997;90(9): 
3799–3805.
 11. Maximova N, Gregori M, Simeone R, et al. Safety and tolerability of 
deferasirox in pediatric hematopoietic stem cell transplant recipients: 
one facility’s five years’ experience of chelation treatment. Oncotarget. 
2017;8(38):63177–63186.
 12. Rouan MC, Marfil F, Mangoni P, Séchaud R, Humbert H, Maurer G. 
Determination of a new oral iron chelator, ICL670, and its iron com-
plex in plasma by high-performance liquid chromatography and ultra-
violet detection. J Chromatogr B Biomed Sci Appl. 2001;755(1–2): 
203–213.
 13. Mattioli F, Puntoni M, Marini V, et al. Determination of deferasirox 
plasma concentrations: do gender, physical and genetic differences 
affect chelation efficacy? Eur J Haematol. 2015;94:310–317.
 14. Cappellini MD, Taher A. Long-term experience with deferasirox 
(ICL670), a once-daily oral iron chelator, in the treatment of transfusional 
iron overload. Expert Opin Pharmacother. 2008;9(13):2391–2402.
 15. EXJADE® (deferasirox) SmPC. Novartis Pharmaceuticals; 2013. Avail-
able from: http://www.ema.europa.eu/ema/. Accessed July 20, 2018.
 16. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chela-
tion by iron intake and serum ferritin: the prospective EPIC study 
of deferasirox in 1744 patients with transfusion-dependent anemias. 
Haematologica. 2010;95(4):557–566.
 17. The European Medicines Agency. EudraVigilance – European Data-
base of suspected adverse drug reaction reports. Available from: http://
www.adrreports.eu/index.html. Accessed December 20, 2017.
 18. National Institutes of Health, US Department of Health and Human 
Services. LIVERTOX. Available from: https://livertox.nlm.nih.gov. 
Accessed December 22, 2017.
 19. Waldmeier F, Bruin GJ, Glaenzel U, et al. Pharmacokinetics, metabo-
lism, and disposition of deferasirox in beta-thalassemic patients with 
transfusion-dependent iron overload who are at pharmacokinetic steady 
state. Drug Metab Dispos. 2010;38(5):808–816.
 20. Tanaka C. Clinical pharmacology of deferasirox. Clin Pharmacokinet. 
2014;53(8):679–694.
 21. Scheiner B, Lindner G, Reiberger T, et al. Acid-base disorders in liver 
disease. J Hepatol. 2017;67(5):1062–1073.
 22. Dubourg L, Laurain C, Ranchin B, et al. Deferasirox-induced renal 
impairment in children: an increasing concern for pediatricians. Pediatr 
Nephrol. 2012;27(11):2115–2122.
 23. Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome. 
QJM. 2014;107(4):261–269.
 24. Baum M. Renal Fanconi syndrome secondary to deferasirox: where 
there is smoke there is fire. J Pediatr Hematol Oncol. 2010;32(7): 
525–526.
 25. Pham AQ, Xu LH, Moe OW. Drug-induced metabolic acidosis. 
F1000Res. 2015;4:4.
 26. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. 
Clin J Am Soc Nephrol. 2009;4(2):481–508.
 27. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the 
probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2): 
239–245.
 28. Dell’Orto VG, Bianchetti MG, Brazzola P. Hyperchloraemic metabolic 
acidosis induced by the iron chelator deferasirox: a case report and 
review of the literature. J Clin Pharm Ther. 2013;38(6):526–527.
 29. Marano M, Bottaro G, Goffredo B, et al. Deferasirox-induced serious 
adverse reaction in a pediatric patient: pharmacokinetic and pharma-
cogenetic analysis. Eur J Clin Pharmacol. 2016;72(2):247–248.
 
Th
er
ap
eu
tic
s 
an
d 
Cl
in
ica
l R
isk
 M
an
ag
em
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
25
1.
17
2.
10
 o
n 
11
-S
ep
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
